Phase 3, single-center, sequential and parallel-group, double-blind, randomized study evaluating the efficacy and safety of Fexofenadine Hydrochloride 180 mg (Allegra®/Telfast®) versus placebo in subjects suffering from Allergic Rhinitis with symptoms aggravated in presence of pollutants: analysis of individual symptom scores

Authors
Category Primary study
JournalWorld Allergy Organization Journal
Year 2020
This article has no abstract
Epistemonikos ID: 194c69c47f6a70ddbb2ad5a03ffe8533b9e5179d
First added on: Feb 12, 2025